Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine …
Over the last 12 months, insiders at Anixa Biosciences, Inc. have bought $441,280 and sold $0 worth of Anixa Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Anixa Biosciences, Inc. have bought $470,041 and sold $42,126 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KUMAR AMIT (Chief Executive Officer) — $313,700. Titterton Lewis H jr (director) — $217,680. Baskies Arnold M (director) — $51,750.
The last purchase of 5,580 shares for transaction amount of $18,023 was made by Titterton Lewis H jr (director) on 2024‑07‑31.
2024-07-31 | director | 5,580 0.0182% | $3.23 | $18,023 | +4.95% | |||
2024-07-30 | director | 21,646 0.067% | $3.06 | $66,237 | +10.78% | |||
2024-07-26 | director | 7,700 0.0239% | $3.03 | $23,331 | +4.59% | |||
2024-07-26 | director | 5,000 0.0158% | $3.09 | $15,450 | +4.59% | |||
2024-07-25 | director | 796 0.0024% | $2.81 | $2,237 | +10.38% | |||
2024-06-14 | director | 4,000 0.0128% | $2.68 | $10,720 | +20.69% | |||
2024-06-13 | director | 405 0.0013% | $2.70 | $1,094 | +15.81% | |||
2024-06-11 | director | 7,102 0.0225% | $2.66 | $18,891 | +20.23% | |||
2024-06-10 | director | 330 0.001% | $2.60 | $858 | +17.98% | |||
2024-06-07 | director | 10,738 0.0332% | $2.52 | $27,060 | +23.53% | |||
2024-06-07 | Chief Executive Officer | 25,000 0.0738% | $2.41 | $60,250 | +23.53% | |||
2024-06-07 | President, COO, & CFO | 6,250 0.0184% | $2.40 | $15,000 | +23.53% | |||
2024-04-09 | director | 15,009 0.0475% | $3.28 | $49,230 | -5.23% | |||
2024-03-15 | Chief Executive Officer | 30,000 0.0821% | $3.22 | $96,600 | -15.45% | |||
2024-03-15 | director | 10,000 0.0308% | $3.63 | $36,300 | -15.45% | |||
2023-07-31 | Sale | Chief Executive Officer | 11,800 0.0371% | $3.57 | $42,126 | -7.10% | ||
2023-07-20 | President, COO & CFO | 5,500 0.0178% | $3.64 | $20,020 | -7.97% | |||
2022-04-26 | 10,000 0.0345% | $2.79 | $27,900 | +58.58% | ||||
2022-04-21 | President | 5,500 0.019% | $2.66 | $14,630 | +66.67% | |||
2022-04-20 | President | 2,509 0.0083% | $2.53 | $6,348 | +65.88% |
Titterton Lewis H jr | director | 896334 2.7854% | $3.20 | 67 | 1 | +4.15% |
KUMAR AMIT | Chief Executive Officer | 516925 1.6064% | $3.20 | 53 | 1 | +9.95% |
Baskies Arnold M | director | 115000 0.3574% | $3.20 | 10 | 0 | <0.0001% |
Catelani Michael | President, COO, & CFO | 35211 0.1094% | $3.20 | 5 | 0 | +42.61% |
KRUSOS DENIS A | Chief Executive Officer | 1969880 6.1215% | $3.20 | 1 | 0 | 0% |
The Vanguard Group | $4.35M | 4.35 | 1.39M | 0% | +$0 | <0.0001 | |
Laird Norton Trust Company Llc | $1.89M | 1.89 | 604,235 | +63.82% | +$734,447.92 | 0.22 | |
UBS | $1.67M | 1.68 | 536,307 | -7.63% | -$138,125.53 | <0.0001 | |
Mission Wealth | $1.57M | 1.57 | 502,420 | +0.25% | +$3,906.24 | 0.04 | |
Susquehanna International Group | $1.06M | 1.07 | 340,951 | +365.13% | +$835,061.67 | <0.01 |